UK Markets closed

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
9.550.00 (0.00%)
At close: 10:51AM EDT
Full screen
Loading interactive chart…
  • EQS Group

    Abivax presents first-half 2022 financial results and operations update

    DGAP-News: ABIVAX / Key word(s): Half Year ResultsAbivax presents first-half 2022 financial results and operations update 15.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE Obefazimod global pivotal phase 3 clinical program in ulcerative colitis on track with US IRB approval granted and first-patient-in expected end of September 2022 Excellent results from the obefazimod phase 2b

  • EQS Group

    Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology

    DGAP-News: ABIVAX / Key word(s): StudyAbivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology 06.09.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY Phase 2b induction trial and 48-week extension results of obefazimod in ulcerative colitis (UC) published i

  • EQS Group

    Abivax publishes a prospectus in the context of its capital increase

    DGAP-News: ABIVAX / Key word(s): MiscellaneousAbivax publishes a prospectus in the context of its capital increase 02.09.2022 / 20:40 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PUBLISHES A PROSPECTUS IN THE CONTEXT OF ITS CAPITAL INCREASE PARIS, FRANCE, September 2, 2022 – 20.30 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune system to develop novel treatment